The Effect of PERT on Patients Undergoing Pancreaticoduodenectomy

Launched by RUIJIN HOSPITAL · Nov 1, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the effects of pancreatic enzyme replacement therapy (PERT) in patients who are undergoing a surgery called pancreaticoduodenectomy, which is often needed for conditions affecting the pancreas. The goal is to understand how PERT can help improve recovery after surgery, reduce complications, and enhance the overall quality of life for patients experiencing pancreatic exocrine insufficiency, a condition where the pancreas does not produce enough enzymes to digest food properly.

To be eligible for this trial, participants should be between 18 and 80 years old and need to be having this surgery for benign or malignant diseases. Women who are pregnant or breastfeeding, and patients with advanced cancer that has spread to other parts of the body, are not eligible. Those who join the trial can expect a personalized approach to their nutrition management before, during, and after the surgery, focusing on their specific health needs and risks. The trial is currently recruiting participants and aims to provide valuable insights into improving care for patients undergoing this type of surgery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Gender unlimited, 18-80 years old;
• • Patients undergoing pancreaticoduodenectomy due to various benign or malignant diseases;
• • Voluntary testing with informed consent.
• Exclusion Criteria:
• • Pregnant women and lactating women
• • Patients with distant metastasis based on tumor staging before surgery;
• • Tumor recurrence;
• • Refuse to sign the consent form.